Nancy Harrison - Knight Therapeutics Independent Director
| GUD Stock | CAD 5.27 0.05 0.96% |
Director
Ms. Nancy Harrison is Director of the Company. Nancy Harrison is former Cofounder and President of MSI Methylation Sciences, a private venture backed development company with a novel treatment of depression in a Phase II clinical trial. She is a former Partner and Senior Vice President of Ventures West Management Inc. Ms. Harrison spent 13 years with Ventures West leading its life sciences practice in Canada and the U.S. She is one of the most experienced life sciences investors in the Canadian VC industry and was instrumental in Ventures West involvement in the sector and with companies such as Angiotech Pharmaceuticals Inc., AnorMed Inc., Salmedix Inc. and Oncogenix Pharmaceuticals Inc., Celator Pharmaceuticals Inc., and Caprion BioSciences. During her time with Ventures West, the firm grew from approximately 80 million to over 750 million since 2018.
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8 |
| Phone | 514 484 4483 |
| Web | https://www.gud-knight.com |
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Simon Pelletier | Stella Jones | 52 | |
| Pierre Pomerleau | Richelieu Hardware | N/A | |
| Dayna Spiring | Winpak | N/A | |
| Pierre Lortie | ECN Capital Corp | 72 | |
| James Manzi | Stella Jones | 69 | |
| Mary Webster | Stella Jones | 65 | |
| Donald Chatterley | Winpak | N/A | |
| David Morris | ECN Capital Corp | 64 | |
| Martti AarnioWihuri | Winpak | N/A | |
| Carol Goldman | ECN Capital Corp | 61 | |
| Karen Martin | ECN Capital Corp | 54 | |
| Karen Albrechtsen | Winpak | N/A | |
| Robert Coallier | Stella Jones | 58 | |
| Karen Laflamme | Stella Jones | 56 | |
| Marc Poulin | Richelieu Hardware | 52 | |
| Paul Damp | Element Fleet Management | 63 | |
| Alexander Greene | Element Fleet Management | 60 | |
| Mathieu Gauvin | Richelieu Hardware | N/A | |
| Ilkka Suominen | Winpak | N/A | |
| Rubin McDougal | Element Fleet Management | 62 | |
| Robert Courteau | Richelieu Hardware | N/A | |
Knight Therapeutics Leadership Team
Elected by the shareholders, the Knight Therapeutics' board of directors comprises two types of representatives: Knight Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Knight. The board's role is to monitor Knight Therapeutics' management team and ensure that shareholders' interests are well served. Knight Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Knight Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Ex Chairman | ||
| Monica Percario, Global Affairs | ||
| Jonathan Goodman, Chief Executive Officer, Director | ||
| Robert Lande, Independent Director | ||
| Samira Sakhia, President, Chief Financial Officer, Director | ||
| BA LLB, Executive Chairman | ||
| Michael Tremblay, Independent Director | ||
| Susan Emblem, Global Resources | ||
| Nancy Harrison, Independent Director | ||
| Sylvie Tendler, Independent Director | ||
| Stephani Saverio, Vice Development | ||
| Meir Jakobsohn, Director | ||
| Henrique Dias, Global Marketing | ||
| Jeff Martens, Global Commercial | ||
| James Gale, Independent Chairman of the Board | ||
| Arvind Utchanah, Chief Financial Officer | ||
| Leopoldo Bosano, VicePresident Operations | ||
| Jody Engel, Senior Director - Business Development | ||
| Amal Khouri, Vice President - Business Development | ||
| Janice Murray, Independent Director | ||
| Nicolas Sujoy, Independent Director | ||
| Daniela Marino, Global Compliance | ||
| Melanie Groleau, Global Clinical |
Knight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Knight Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 133.90 X | ||||
| Revenue | 328.2 M | ||||
| EBITDA | 56.82 M | ||||
| Net Income | (16.84 M) | ||||
| Cash And Equivalents | 302 K | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 69.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.31 X | ||||
| Book Value Per Share | 7.53 X |
Pair Trading with Knight Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Knight Stock
| 0.81 | ONEX | Onex Corp | PairCorr |
| 0.77 | SU | Suncor Energy | PairCorr |
| 0.76 | ENB | Enbridge | PairCorr |
| 0.56 | X | TMX Group Limited | PairCorr |
| 0.53 | MGA | Mega Uranium | PairCorr |
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.